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ABSTRACT 
 
Regulating rsmA Expression in Pseudomonas aeruginosa 
by 
Sean D. Stacey 
 
Pseudomonas aeruginosa, a Gram-negative bacillus, commonly infects immunocompromised 
individuals and uses a variety of virulence factors to persist in these hosts. The 
posttranscriptional regulator, RsmA, plays a role in the expression of many virulence factors in 
P. aeruginosa.  RsmA up regulates virulence factors used in colonizing hosts.  However, 
regulation of rsmA is not well elucidated. Transposon mutagenesis was performed on P. 
aeruginosa containing a transcriptional rsmA-lacZ fusion to answer this question.  Mutants were 
screened via β-galactosidase assay and transposon insertions identified via arbitrary PCR.  A 
probable MFS transporter, we named mtpX, was one significant transposon mutant identified. A 
∆mtpX mutant containing the rsmA-lacZ transcriptional fusion was constructed to confirm our 
results. Further analysis of rsmA, looking at RNA and protein levels, revealed varying results in 
nonmucoid versus mucoid backgrounds. Phenotypic assays were performed to characterize this 
unknown transporter and develop a putative mechanism as to how MtpX affects rsmA 
expression. 
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CHAPTER 1 
INTRODUCTION 
Pseudomonas aeruginosa 
 
 Pseudomonas aeruginosa is a Gram-negative bacillus capable of colonizing a wide variety 
of environments in part because of its ability to metabolize an array of carbon sources (1). 
However, in human hosts the bacterium is an opportunistic pathogen.  P. aeruginosa most 
commonly infects the immunocompromised hosts. Individuals with Human Immunodeficiency 
Virus (HIV) infections, severe burns, or cystic fibrosis (CF) are at an increased risk for P. 
aeruginosa infection (5,40). Additionally, P. aeruginosa is frequently associated with infections 
of the ears, eyes, and the urinary tract (1,10,40). Indeed, P. aeruginosa is capable of infecting 
any tissue in the human body owing to the myriad of virulence factors produced by this 
bacterium. In addition, P. aeruginosa biofilms are recalcitrant to antibiotic therapy and treatment 
of P. aeruginosa infections is difficult. 
Virulence Factors 
 Colonization is a pivotal step for the bacterium in a human host. P. aeruginosa has 2 
virulence factors that aid in the motility of the organism, a single polar flagellum and type IV 
pili(1,10). A flagellum is a tail-like propeller on the cell. An ATP motor in the inner cell 
membrane powers the flagellum. The flagella can be examined in vitro using swimming or 
swarming assays on agar plates of various agar concentrations. While flagella are an important 
virulence factor, flagella are recognized by the innate immune system. Toll-like receptor 
5(TLR5) specifically recognizes the flagellum protein flagellin and stimulates inflammation 
(8,10). P. aeruginosa uses the AprA enzyme to evade the immune response by cleaving the 
flagellum into units TLR5 cannot bind (2). However, without flagellar motility P. aeruginosa is 
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known to be less virulent or attenuated (10). 
 Type IV pili are also used for motility as well as adhering to epithelial cells inside the host. 
These small appendages are composed of multiple proteins that can extend and retract in to the 
bacterial cell (14,25). This type of cellular movement is termed twitching. Like flagella, type IV 
pili are also recognized by the immune system and can activate the inflammasome, a group of 
proteins that produce inflammatory cytokines (23). Pili are important for adeherence to epithelial 
cells as well as form biofilm formation and development (29). 
 P. aeruginosa also possesses the type III secretion system that is important in acute 
infections. This virulence factor is a needle-like projection from the bacterium that directly 
injects bacterial toxins into the host cells leading to cell death (23). P. aeruginosa uses the type 
III secretion system to inject several toxins, like ExoS and ExoT, into the host cell (12). Like 
type IV pili, this virulence factor can also activate the host’s inflammasome (23). The type III 
secretion system is important in acute infections but plays little or no role in chronic infections 
(6). 
 When an acute infection persists or is left untreated, P. aeruginosa can become a chronic 
infection. The change from acute to chronic infection involves a change in the virulence factors 
expressed. For example, type IV pili and the type III secretion system are down regulated when 
P. aeruginosa begins expressing a type VI secretion system and alginate production increases 
(6,29). The type VI secretion apparatus is still not completely understood, but it functions 
similarly to the type III secretion system by infecting enzymatic compouds into host cells or 
unrelated bacteria (6). The down regulation of virulence factors such as type IV pili and the type 
III secretion system may allow P. aeruginosa to persist in the host by preventing its detection 
from the immune system. 
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 A major factor allowing P. aeruginosa to evade the host’s immune system is its ability to 
form biofilms. P. aeruginosa secretes exopolysaccharide in both acute and chronic infection 
states (13). The biofilm creates a protective barrier around the bacterial growth and inhibits 
chemotherapeutic agents from reaching the cell as well as prohibiting phagocytosis by immune 
cells (13). The lungs of individuals with cystic fibrosis create thick, sticky mucus, which acts like 
a biofilm because of a mutation in the cystic fibrosis transmembrane conductance regulator 
protein (7,36). However, when strains of P. aeruginosa are isolated from these individuals, they 
begin to make their own biofilm of alginate similar to that found in the CF lung (6). Alginate has 
been shown to inhibit the activity of reactive oxygen species and to prevent phagocytosis 
(7,13,40). Several regulators of biofilm formation and development have been described (6, 18, 
19, 29) One important regulator of biofilm development and virulence factor regulation is RsmA, 
a posttranscriptional regulator(4). 
RsmA 
 In P. aeruginosa, RsmA, or regulator of secondary metabolites, is a crucial protein that 
regulates many genes including those important for virulence and biofilm formation (4,5). It has 
a predicted molecular weight of 6.9 kilodaltons (kDa)(4). RsmA recognizes the sequence GGA 
on messenger RNA (mRNA) and binds this sequence (4,19). By binding mRNA, RsmA inhibits 
ribosomal attachment and the bound message is not translated (Figure 1). This is a form of direct 
negative regulation. By posttranscriptional regulation RsmA is able to regulate multiple genes, 
most importantly virulence factors. Previous studies have shown that in PAO1 and PA14, RsmA 
regulates virulence factors that initiate colonization like type IV pili, type III secretion system, as 
well as iron acquiring compounds by increasing the expression of these genes (4,5). By binding 
mRNA to be translated to make proteins that would suppress these genes, RsmA is able to 
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increase these acute infection genes’ expression. Conversely, RsmA will also down regulate the 
expression of virulence factors that appear in the chronic infection state (4,5). RsmA also shares 
homology with the Escherchia coli protein CsrA (4,26). 
 
 
Figure 1. Diagram of RsmA function 
  
 RsmA has 2 known antagonists, the small RNAs, RsmY and RsmZ, homologous to CsrB 
and CsrC in E. coli (4). These small RNAs have numerous GGA repeats that can bind more than 
one RsmA at a time (4,19). RsmY and/or RsmZ bind to RsmA and prevent RsmA’s regulatory 
activity (4,19). These antagonists are the downstream effect of a larger system that is affected by 
quorum sensing (QS), one way for cells to respond to environmental stresses (18). The GacA/S 
2-component system, a part of QS, positively regulates the small RNAs that in turn suppress 
RsmA’s functioning(18). 
 13 
 Previous work and our own have demonstrated that RsmA expression is maximal in the log 
phase of growth (4, Figure 2). mucA22 has a single guanine missing in the antisigma factor gene, 
mucA, causing increased alginate production and a mucoid strain phenotype (24). To begin to 
better understand the regulation of RsmA in both the wildtype strain of P. aeruginosa, PAO1, 
and a strain representing a chronic infection state, mucA22 (Figure 2), Western blot analysis was 
performed. The Western Blot analysis shows that RsmA’s presence increases in log phase and 
begins to diminish in stationary phase. We also saw that RsmA is present longer and in greater 
amounts in PAO1 than mucA22(Figure 2). 
 
 
Figure 2. RsmA-HA tagged Western Blot Analysis over 12 hours with 10 μg of protein. We 
analyzed both the nonmucoid strain PAO1 and the mucoid strain mucA22. A negative of control 
of PAO1 without HA-tagged RsmA was used. Samples were taken from a 500 ml broth culture 
seeded with 1% of an overnight culture at 0 time point. 
  
 These data sparked our interest in studying RsmA in the mucA22 strain. Another question 
we wanted to answer was, “What genes are regulating rsmA expression?” Previous microarray 
and and transcriptome analysis in PAO1 and PA14 strains (representations of nonmucoid strains) 
have better defined the role of RsmA in the cell (4,5). 
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Identifying rsmA Regulators 
 Two orphan sensor histidine kinases, RetS and LadS, are important in controlling the 
amount of free RsmA in the bacterial cell (19,27). However, little is known about the regulators 
of rsmA. Additionally, no studies have examined the role of RsmA in the mucoid background. 
 An rsmA-lacZ transcriptional fusion was assayed in the mucA22 strain to begin to 
understand the role of RsmA in chronic-infecting strains. This fusion was designed based on a 
primer extension of rsmA (Figure 3). This extension showed that there are 2 transcriptional start 
sites for rsmA. Both of the promoters for these start sites were included in the fusion. One of the 
putative promoters fits the consensus sequence as an AlgU-dependent promoter (33). This is the 
promoter that is 130 bp upstream of the translational start site of rsmA. The other sigma factor 
regulating the second promoter has yet to be identified. 
 
Figure 3. Primer Extension of rsmA and genomic sequence showing promoters. There are 2 promoters for 
rsmA in PAO1. The distal promoter is an AlgU promoter while the second promoter is still unidentified. 
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 The fusion strain was conjugated with an E. coli strain bearing the pBT20 plasmid that 
contains gentamicin resistance (Gm
R
) and a transposon. Gentamicin-resistant colonies were 
examined for β-galactosidase activity. X-gal containing plates were used to screen colonies and 
those identified as having differential rsmA expression were used in quantitative β-galactosidase 
assays and compared to the parent strain. 
Confirming Transposon Mutant Results 
 After identifying several strains exhibiting differential rsmA expression compared to the 
parent strain, our next goal was to identify the gene interrupted by the transposon. When the 
transposons insert into the genome, they can affect more than one gene if the genes are in the 
same operon. This can cause polar effects downstream of the operon, skewing the β- 
galactosidase assay results, and, therefore, clean knockout mutants of the interrupted genes had 
to be constructed. 
 We make knockout mutants in the nonmucoid background, PAO1, and the mucoid 
background, mucA22. These mutants were subject to growth curve analysis in various broths to 
look for possible defects. Knockouts were also constructed for 2 CF clinical isolate strains, 
FRD1 and 2192, to confirm the results of the mucA22 mutant. The rsmA-lacZ fusion was 
inserted into our knockout mutants and β-galactosidase assays were performed to confirm our 
transposon mutant results and refute downstream effects of the inserted transposon. Because 
transcriptional fusions indirectly monitor gene expression, RNase Protection Assays and Western 
Blot analysis were performed to not only confirm our β-galactosidase results but also to examine 
RsmA protein levels. This would allow us to determine rsmA regulators and further our 
understanding of rsmA regulation. 
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Characterizing the Identified rsmA Regulators 
 Our last aim was to better characterize rsmA regulators identified in our study. In 
particular, we focused on mtpX. We conducted several phenotypic assays based on the visual 
traits of the knockout mutants as well as determining their cellular appearance via electron 
microscopy. As we characterized the phenotype of the knockout mutant, we were able to gain a 
better understanding of the gene’s role of rsmA regulation and describe its mechanisms in both 
nonmucoid and mucoid backgrounds. 
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CHAPTER 2 
MATERIALS AND METHODS 
Bacterial Strains and Growth Conditions 
 Pseudomonas aeruginosa strain PAO1 was used as the wildtype stain and example of a 
nonmucoid background. A strain of PAO1 with the defective antisigma factor mucA, 
mucA22/PDO300, was used to represent a mucoid background. Two clinical isolates, FRD1 and 
2192, isolated from cyctic fibrosis patients, were also used as mucoid strains to demonstrate 
clinical relevance. Escherichia coli SM10 and JM109 strains were used for conjugating various 
plasmids with P. aeruginosa strains. JM109 strains had to be triparentally mated with E. coli 
contain the pR 2013 vector. All strains were grown at 37  C unless otherwise stated. P. 
aeruginosa strains were inoculated on Pseudomonas Isolation Agar(PIA) with the possible 
addition of antibiotics (Appendix) while E. coli strains were inoculated on Luria-Bertani(LB) 
Agar with possible antibiotic variations(Appendix). Fifteen percent Glycerol stocks were made 
for storage of each strain with 500μl of sterile LB broth and 500μl of sterile 30% glycerol. 
Strains were scraped from a plate with a sterile stick and placed into the stock tube. These stocks 
were stored at -80  C. Various plasmids used can be found in the appendix. 
Genomic DNA Isolation 
 For genomic DNA isolation cultures were grown on PIA plates overnight. The cells were 
then scraped from the plate with a sterile stick and washed with 1X TNE(Appendix). Cells were 
placed in 1.7 ml microcentrifuge tubes then pelleted by centrifugation at 13.2x1000 rpm for 2 
minutes. The cells were resuspended in 1.5 ml of 70% ethanol (EtOH) and placed on ice for 15 
minutes. Cells were then centrifuged for 5 minutes and EtOH was poured off and the pellet was 
left to air dry. Cells were resuspended in 446μl of TEST buffer (Appendix), 30μl of 20mg/ml of 
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lysozyme, and 4μl of 10mg/ml RNase A. Cells then were incubated for an hour on ice and then 
frozen at -20  C for 15 minutes. The cells were then incubated at 68  C for 10 minutes.  ifty- three 
μl of 10% SDS(sodium dodecyl sulfate) was added and left at room temperature(RT) for 15 
minutes. Then 87μl of 5M NaCl and 69μl of CTAB(Cetyl trimethylammonium bromide)/NaCl 
solution was then added, vortexed, and left to sit for 15 minutes. Tubes were then placed in - 
20  C for 30 minutes. After thawing, Phenol-Chloroform Extraction was performed. We added 
650μl of 24:25:1 chloroform:phenol:isoamyl alcohol(C:P:I) was added and vortexed. Tubes were 
centrifuged at 13.2x1000 rpm for 10 minutes. The aqueous layer was removed and placed in a 
new microcentrifuge tube with 600 μl TE buffer(Appendix) and 600 μl 24:1 chloroform:isoamyl 
alcohol(C:I). Tubes were vortexed and the spun at 13.2x1000 rpm for 10 minutes. The aqueous 
later was removed again and placed into a new microcentrifuge tube. Salt and nucleic acid was 
precipitated with 1 ml of 95% EtOH and put on ice for 15 minutes. Tubes were centrifuged at 
13.2x1000 rpm for 10 minutes and EtOH was poured off. One and a half milliliters of 70% EtOH 
was then added, mixed, and centrifuged for 10 minutes. The remaining EtOH was poured off and 
pellets were left to air dry. After the EtOH had evaporated completely, DNA pellets were 
resuspended in 50 μl of double distilled H2O(ddH2 ). DNA extracted was confirmed via 
electrophoresis on 1% agarose gel (Appendix) and samples were stored at 4  C. 
Transposon Mutagenesis 
 A transposon mutant library was created by conjugating the pBT20 vector containg the 
mariner transposon and Gm
R 
with a mucA22 strain contain an rsmA-lacZ fusion (3,34). The E. 
coli strain was grown up overnight in 5ml of LB broth with 15 μg/ml of gentamicin while the P. 
aeruginosa strain was grown in 5ml of LB broth. After overnight growth, the P. aeruginosa 
culture was incubated at 42  C for 2 hours. Both cultures were then centrifuged at 7000 rpm for 5 
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minutes and resuspended together in 500 μl of 0.85% NaCl. The mixed strains were then 
vortexed and dispensed into the middle of a LB plate for 1.5 hours at 30  C. The plate was then 
scraped and the cells were again resuspended in 500 μl of 0.85% NaCl. These cells were then 
spread-plated over four 150 μg/ml gentamicin PIA plates and incubated at 37  C overnight. 
Gentamicin-resistant colonies appeared 1 to 2 days after incubation at 37oC. 
Patch Plating 
 Individual colonies were picked from the PIA gentamicin plates with a sterile toothpick 
and patch-plated on to a 80 μg/ml 5-bromo-4-chloro-3-indolyl-β-D-galactopyranoside( -gal) 
PIA gentamicin plate. There were 52 colonies patched per plate. These plates were then 
incubated at 37  C overnight. A blue color was evident from the mucA22 strain carrying the 
rsmA-lacZ fusion after 24 hours. This strain was used to compare the transposon mutant library. 
Transposon mutant patches with lighter or darker blue appearance compared to the parent strain 
were then further analyzed. 
β-Galactosidase Assay 
 Transposon mutants identified in the patch plate assay for differential rsmA expression 
were tested in a quantitative β-galactosidase assay (28). Strains were grown overnight on 
gentamicin PIA plates or mucA22 rsmA-lacZ on PIA plates or in 16 hour LB broth culture 
(gentamicin added for transposon mutants to 20μg/ml). Pellets of cultures were collected either 
with 1ml of 1  TNE and scraping from a plate or 350 μl of broth culture and centrifuged. Cells 
were resuspended in 1 ml of Z Buffer (Appendix) and optical density (O.D.) 600nm was 
measured. Samples needed to be between 0.4 – 1.0.  ifty μl of 0.1% SDS and 100 μl of 
chloroform were then added to each sample and vortexed for 15 seconds. Samples were left to 
set for 10 minutes. One hundred microliters of supernatant was removed and placed in a new 
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microcentrifuge tube with 800 μl of Z buffer. 200 μl of ortho-Nitrophenyl-β-galactoside(ONPG) 
solution (4 mg/ml ONPG in Z buffer) was added to each sample and reaction time was recorded 
until samples turned a yellow color. At the time point of yellow color, 500 μl of 1M Na2CO3 was 
added to stop the reaction. O.D. 420nm and 550nm was then recorded. Values were then 
substituted into the Miller Units. 
 Equation: 
  1000 x (O.D.420nm -1.75x O.D. 550nm) =   Miller units of  
  Time x Volume of sample x O. D. 600nm     β-galactosidase activity 
 
Arbitrary PCR 
 Transposon mutants having differential β-galactosidase activity were then subject to 
arbitrary PCR to amplify flanking regions of the mutant chromosome adjacent to the transposon 
(30). Taq DNA polymerase and Thermopol Buffer were purchased from New England Biolabs 
(NEB). A revised version of the George  ’Toole and  olter protocol is as follows (Table 1). 
Perform genomic DNA isolation on mutant and digest with either EcoR1 or BamH1 restriction 
enzyme. 
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 The PCR#1 product in Table 2 is simply 1.5 μl of the 50 μl volume without clean up or gel 
extraction. Products of PCR#2 were run on a 1.5-2% agarose gel to confirm amplification then 
cleaned up via Promega Wizard® SV Gel and PCR Clean-Up System. Samples were then sent to 
the ETSU Molecular Biology Core for sequencing. 
Mutant Construction 
 To confirm transposon mutant results knockout mutants were constructed. This was 
performed so that any polar effects due to transposon insertion in the mutant library were 
nullified. 
Splicing by Overlap Extension 
 Two sets of primers, F1 & R2 and R1 & F2, (Appendix) were designed around the gene of 
interest (17). F1 is at a region 1000 bases upstream from the gene while R1 is 1000 bases 
downstream. The F1 and R1 primers both have 4 random nucleotides at their 5’ end and then an 
endonuclease site of choice. The endonuclease chosen usually is found in not only a cloning 
vector but a suicide vector as well and cannot cut the sequence being amplified. F2 and R2 are 
slightly more complex. R2 is on the bottom strand under the translational start of the gene 
usually between an 18 to 20-mer. This sequence is then reverse complemented and starts the 5’ 
piece of the F2 primer. F2 is on the top strand including the translational stop of the gene and this 
18 to 20-mer is also reverse complemented and starts the 5’ of the R2 primer. These reverse 
complements will create overhangs on the first fragments that will aid in annealing the segments 
together in the second PCR. A 1000 base pair (bp) fragment was amplified upstream(5’ segment) 
and downstream(3’ segment) of the gene. In a second PCR, both of these fragments were spliced 
together via regions of homology on the F2 & R2 primers and then amplified to 
create a knockout construct. The  1 & R1 primers also had restriction enzyme sites on the 5’ end 
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so that ligating with a suicide vector, pEX18Tc, would be easier. After each PCR the amplified 
segment was gel extracted and put through the Promega Wizard® SV Gel and Clean- Up 
System. This clean up system removes any debris from the agarose gel and purifies our amplified 
segments. 
Plasmid DNA Isolation 
 Cultures were grown overnight with appropriate antibiotics in 5ml of LB broth. On the 
second day the culture was spun down in a centrifuge at 7000 rpm for 10 minutes. The LB broth 
was poured off and the pellet was resuspended in 150 μl TE. This suspension was transferred to a 
microcentrifuge tube and 300 μl of 1% SDS/ 0.2M Na H was added and mixed. The tube was 
incubated on ice for 5 minutes. 225 μl of potassium acetate/acetic acid (5M potassium acetate 
and 11.5% acetic acid) was then added along with 4μl of 10mg/ml RNase A, mixed, and then 
incubated on ice for 5 minutes. The tubes were then centrifuged at maximum speed for 10 
minutes in a microcentrifuge and the supernatant transferred to a new tube. Phenol-Chloroform- 
Isoamyl alcohol was added in equal volume, vortexed, and centrifuged for 5 minutes. The 
aqueous phase was removed to a new tube and the plasmid DNA precipitated using 95% EtOH 
and incubation on ice for 10 minutes. The plasmid DNA pellet was washed with 70% EtOH, the 
pellet air dried, and the plasmid DNA was resuspended in 50 μl of ddH2  and stored at -20 or 
4  C. 
Double Digest & Ligation 
 Both the knockout construct and suicide vector were individually double digested with the 
necessary restriction enzymes to produce sticky ends on both products (Table 3). 
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 If possible, restriction enzymes were inactivated using heat inactivation or using Promega 
enzymatic cleanup protocol. After double digest was performed, a new microcentrifuge tube was 
used for the ligation with a 1:3 molar ratio of plasmid to knockout construct. The molar amount 
of a DNA sample can be calculated by quantifying it using the spectrophotometer at A260. 
Calculating the μg/ml by multiplying the value from A260 * 50 * 100. Then dividing this 
amount by 0.66*size of DNA segment. 0.66 is the average weight of 1 base pair of nucleotides 
(38). ddH2O, T4 DNA ligase buffer, and T4 DNA ligase were added to the tube and put at 4  C 
overnight (Table 4). To confirm the ligation  
 
was successful, 3 μl of the volume was removed before adding the T4 DNA ligase and run on a 
1% agarose gel with 3 μl of the post ligation volume. The preligation lane should contain 2 
bands, the insert and the plasmid, while the postligation lane can contain a smear and no insert 
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band. 
Transformation 
 After ligation, 100-150 μl of competent E. coli SM10 or  M109 cells were placed on ice 
and 5 μl of the post ligation mix was added and incubated for 10 minutes. This mixture was 
placed at 42  C for 45 seconds to 1 minute and then placed on ice for 2 minutes. One milliliter of 
LB broth was added to the microcentrifuge tube and placed on a shaker at 37  C for 1 hour to 
rescue. The cells were pelleted and spread-plated on to an LB plate with the appropriate 
antibiotic for the suicide vector to be expressed as a form of positive selection. Colonies were 
screened using blue-white selection. White colonies were grown up overnight in LB with the 
appropriate antibiotic and plasmid DNA isolated and digested with the appropriate restriction 
enzymes to confirm insertion of the amplified construct into the suicide vector.. The final suicide 
construct was verified by sequencing at the ETSU Molecular Biology Core facility. 
Homologous Recombination 
 In order to perform allelic exchange, the suicide construct was conjugated into various P. 
aeruginosa srains using tri-parental or bi-parental mating. Merodiploid colonies were obtained 
by selecting for antibiotic resistant colonies postconjugation indicating that the suicide construct 
had inserted into the bacterial chromosome. Merodiploids placed in 5 ml of LB broth overnight 
without selection in order to allow for a second cross-over event. Due to counter-selectable 
marker sacB, gene on the suicide vector, coding for the protein levansucrase, sucrose counter- 
selection was used to detect bacteria that had undergone the second recombination event. Serial 
dilutions of 10
-4
, 10
-6
, and 10
-7 
were performed on LB 10% Sucrose plates. Sucrose-resistant 
colonies were patch plated onto antibiotic plates and PIA plates. Bacteria only growing on PIA 
were screened via internal primers to detect wildtype or mutant variation. 
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Growth Curve 
 Cultures of P. aeruginosa were initiated in a 5 ml LB broth overnight. On day 2, the 
absorbency at O.D. 600nm was measured and diluted to 0.1. A 99 ml broth, either LB or minimal 
media, was seeded with 1 ml of the diluted culture. O.D. 600nm reading was taken every 3 
hours. The experiment was performed in triplicate. Minimal media consisted of M9 salts 
(Appendix) and either 1% glucose or 1% succinate as a carbon source. 
Construction of rsmA-lacZ Transcriptional Fusion Strains 
 Mutant strains were conjugated, in the same fashion as the suicide vector in the mutant 
construct section, with the mini-CTX-lacZ plasmid containing the rsmA-lacZ fusion (39). mini- 
CTX-lacZ uses the attB site on the P. aeruginosa chromosome for insertion. By doing so, it is 
inserted as a single copy, unlike other complementation vectors that have multiple copies in the 
cell. Colonies with tet
R 
were than grown up overnight and conjugated with an E. coli strain 
containing the plasmid pFLP2 to flip out the mini-CTX plasmid vector backbone and leave the 
rsmA-lacZ fusion. This conjugation was then streaked for isolation on VBMM Carb300 plates 
(Appendix). The isolated colonies were patch plated on to LB tet irg (Appendix) and PIA plates 
to confirm the loss of the tet
R 
gene. Growth overnight at 37°C without selection was used to cure 
the P. aeruginosa strains of pFLP2. Colonies grown on PIA and killed on VBMM Carb300 were 
then screened for the rsmA-lacZ insert via rsmA forward and lacZ reverse primers (Appendix). 
RNA Isolation 
 Cultures of P. aeruginosa were grown in 5 ml of LB broth for 6 to 8 hours (37). Three 
hundred microliters of the culture was aliquoted into a microcentrifuge tube and pelleted at 7000 
rpm for 5 minutes.  LB broth was poured off and 1 ml of TRIzol® (Invitrogen) was used to 
resuspend the pellet.  Five hundred μl of glass beads were added and beat for 3 intervals at 20 
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seconds. Tubes were intermittently placed on ice. Tubes were left to set for 10 minutes. The 
TRIzol®/cellular mix was then removed and added to a clean microcentrifuge tube with 200μl of 
chloroform. Tubes were inverted for 2 minutes and then centrifuged for 10 minutes. Supernatant 
was then added to the column of the Promega SV Total RNA Isolation System. The Promega SV 
Total RNA Isolation System protocol was then followed. After 2 elutions, 20μl of sodium acetate 
was added and 500μl of 95% Et H was followed. Tubes were incubated at -20  C for 15 minutes. 
Tubes were then centrifuged for 10 minutes and EtOH was poured off. 1 ml of 70% Et H was 
placed on top of the RNA/salt pellet and tubes were stored at -80  C until used. All reagents used 
DEP-C treated or nuclease free water. Successful RNA isolation was confirmed via 
electrophoresis with an 1% agarose/formaldehyde gel(). Quantifying RNA was done with 5 μl of 
RNA sample in 495 μl of TE. Absorbance was measured at  .D. 260 and 280. Purity was 
confirmed by the ratio A260/A280, while amounts were estimated by multiplying A260 x 
40(representative of weight) x 100 (dilution factor). 
RNAse Protection Assay 
 The RPA IIITM Ribonuclease Protection Assay Kit (Ambion®) was used for this assay. 
The protocol with this kit was followed and used to design and make a biotinylated probe for 
rsmA mRNA. The rsmA probe is a single strand of antisense RNA to the mRNA of interest, in 
this case rsmA’s mRNA. The probe was made via primers (Appendix) for rsmA with a reverse 
primer also containing a promoter for T7 phage RNA polymerase (Ambion RPAIII Kit). The 
sequence was transcribed via the RNA polymerase and then gel extracted from an 8M urea/ 
5%acrylamide gel (Table 5). The probe was aliquoted and stored at -20oC. After aliqoting the 
probe, the 5 μg of RNA samples and a negative control of yeast RNA were added to a clean 
microcentrifuge tube and 3 μl of a 200-fold diluted probe were hybridized with hybridization 
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buffer over night at 42°C. A solution of RNase Digestion Buffer 3 and RNase A/T1 was made 
with 150μl Digestion Buffer 3:1μ RNase per tube. The RNase was not added to the probe by 
itself. These samples were then incubated for 30 minutes at 37°C. After, 225μl of Inactivation 
Solution was added and the samples were incubated at -20°C for 15 minutes. The tubes were 
centrifuged for 15 minutes at maximum speed. The supernatant was removed and 10 μl of 
loading buffer was added. The samples were heated at 92°C for 5 minutes and then placed in 
slushy ice. Samples of RNA and probe were run on a 5% acrylamide / 8M urea gel (Table 5) and 
run  
 
in 1X TBE buffer (Appendix) at 200 V. The gel was electroblotted in 0.5X TBE for 1 hour at 
150 mA on to a nitrocellulose membrane. The membrane was then UV crosslinked for 30 
seconds. The BrightStar® BioDetectTM Kit (Ambion®) was then used detect protected RNA 
samples on the membrane. The kit’s protocol was followed. To visualize the samples a 
ProteinSimple FluorChem M system was used with the chemiluminescence option. 
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Insertion of rsmA-HA Tag 
 The suicide vector pEX18Gm was used to clone the rsmA gene with hemaglutinin(HA) tag 
added to the 3’ end of the rsmA gene. This vector was conjugated as described previously into 
various P. aeruginosa strains. Primers rsmA SDM check F(forward) and rsmA R check(reverse) 
were used to detect the addition of the HA portion on to rsmA (Appendix). 
Western Blot Analysis 
 Cultures of P. aeruginosa were either grown in LB broth or harvested from LB plates after 
12 hours. Cells were pelleted in 2 ml tubes and resuspended in 0.85% NaCl to a final volume of 
1.7 ml. Tubes were left on ice. Thirty microliters of 20mg/ml of lysozyme was added to help lyse 
of the cells. Sonication was performed for each tube for 20 seconds twice. Intermittently, tubes 
were left on ice between sonication. Tubes were centrifuged at 7000 rpm for 10 minutes to pellet 
debris. Supernatant was removed and placed into a new microcentrifuge tube. A standard curve 
was created using the Bio-Rad Protein Assay and BSA at concentrations of 0.0625 mg/ml, 0.125 
mg/ml, 0.25 mg/ml, 0.5 mg/ml, 1.0 mg/ml, and 2.0 mg/ml. Ten milliliters of colorimetric assay 
dye was added to 40 ml of ddH2O. Thirty microliters of each BSA sample was added to 3.5 ml of 
the assay dye solution. Thirty microliters of each HA-tagged sample’s supernatant was also 
added to 3.5 ml of assay dye solution to quantify the amounts of protein against the standard 
curve. All samples were measured at O.D. 595nm. The BSA samples were then analyzed in 
Excel and a standard curve generated. The amount of protein in the cellular samples was 
calculated from the trend line equation. Only R
2 
values of 0.98 or higher were used. Ten 
micrograms of cellular samples were mixed with a 4  SDS PAGE loading dye (Appendix). The 
samples were heated for 5 minutes at 92  C, briefly centrifuged, and put in slushy ice. A 
discontinuous SDS-PAGE gel of 4% stacking/15% separating (Table 6) was used for the RsmA-
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HA Western Blot. Samples were run at 180 V until the dye front  
 
reached the end of the separating gel. The gel was run in 500 ml of 1X Glycine Running Buffer 
(Appendix). To prepare for transferring to a polyvinylidene fluoride (PVDF) membrane, 1X 
Towbin Buffer (Appendix) and 10%methanol were used for transfer to the PVDF membrane 
after soaking in methanol for 10 minutes The transfer apparatus was assembled and run at 150 
mA for 1.5 hours. 
 After transferring, the membrane was removed from the sandwich and placed in Blocking 
Buffer (Appendix). This was rocked for 2 hours at RT. The Blocking Buffer was poured off and 
1  antibody for HA was added (Appendix) at a 1:10,000 dilution. This was rocked at 4  C 
overnight. On day 2, the antibody wash was poured off and washed 3 times with Washing Buffer 
(Appendix) for 15 minutes each time. The 2  antibody (goat anti-mouse) containing conjugated 
horseradish peroxidase was added (Appendix) at a 1:10,000 dilution for 1 hour and rocked at RT. 
The antibody wash was poured off and washed again 3 times for 15 minutes each time. Lastly, 
the Pierce ECL Western Blotting Substrate kit was used to visualize the proteins tagged on the 
membrane. 3 ml of Substrate A and 75 μl of Substrate B were mixed and poured over the 
 31 
membrane. The membrane was hand rocked for 5 minutes. The membrane was then transferred 
to the ProteinSimple FluorChem M visualizer for data analysis. 
Swimming Assay 
 LB plates (0.3% agar) were used in this experiment (22). Cultures of P. aeruginosa were 
grown up overnight and transferred to swimming plates via a sterile toothpick. Plates were 
stabbed with the inoculated sterile toothpick and incubated at 30  C for 48 hours. The zone of 
growth was measured in centimeters. Experiments were performed in triplicate. 
Twitching Assay 
 LB plates (1.5% agar) were used in this experiment (22). Cultures of P. aeruginosa were 
grown up overnight and transferred to twitching plates via a sterile toothpick. Plates were 
stabbed with the inoculated sterile toothpick and incubated at 30  C for 48 hours. Agar was 
removed with a sterile stick and 1% crystal violet was used to flood the plate and left to set for 5 
minutes. This stain was used to visualize the twitching zones. The crystal violet was washed with 
water and twitching zones were measured in mm. Experiments were performed in triplicate. 
Transmission Electron Microscopy (TEM) 
 Cultures were streaked for isolation and grown up on PIA plates overnight. 5 μl of ddH2O 
was added to a Formvar/Carbon film coated, 200 Mesh, Cu, TEM grid. To this drop of water, a 
single colony was picked with a sterile toothpick and touched for 5 minutes to the water(14). 
 ive μl of 1% uranyl acetate (UA) was added to the drop of water and left to set for 45 seconds. 
The drop was then wicked with sterile chromatography paper from the other side of the grid 
where the drop was placed. Grids were stored in a carrier and taken to the TEM facility.  
Microscopy was performed with a Philips Tecnai 10 transmission electron microscope with an 
acceleration of 80 kV. 
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Iron Acquisition on Chrome Azurol S Plates 
 Chrome Azurol S(CAS) plates were used to study the degree of iron acquisition of 
wildtype versus mutant strains (21). Iron III solution consisted of 27 mg FeCl3 •6H2 , 83.3 μl of 
12M HCl, and 100 ml ddH2O. Basal Agar Medium consisted of 415 ml ddH2O, 15g of 3-(N- 
morpholino)propanesulfonic acid (MOPS), 0.25 g NaCl, 0.15g KH2PO4, 0.05g NH4Cl, 2.5g of L- 
asaparagine. The pH of solution was measured to 6.8 with 5M NaOH and 7.5g of agar was added 
and then autoclaved. CAS indicator solution consisted of: Solution A, 60.5mg Chrome azurol S 
and 50ml of ddH2O, after dissolving, 10ml of Iron III solution was added, Solution B, 72.9mg 
hexadecyltrimethyl ammonium bromide (HDTMA) and 40ml of ddH2O. Solution B was slowly 
added to Solution A and autoclaved. After autoclaving and allowing the basal agar medium to 
cool, 10ml of 50% succinate and 50ml of the CAS indicator solution were added and mixed. 
Cultures of P. aeruginosa were grown overnight and transferred to CAS plates via a sterile 
toothpick. Plates were stabbed with the inoculated sterile toothpick and incubated at 30  C for 48 
hours.  
Biofilm Assay 
 The microtiter dish biofilm formation assay described by  ’Toole was performed on 
wildtype and ΔmtpX mutants as well as Congo Red media (22,31). LB broth cultures were grown 
overnight and the next day diluted 1:100 in M63 broth (Appendix). One hundred microliters of 
the dilution was added to a row of wells on a 96-well flat bottom plate. The dish was incubated 
for 24 hours at 37  C. Plates were washed 2 times with ddH2  and then 125 μl of 1% CV was 
added to each well and set for 10 minutes. The plate was washed 3 times with ddH2O to remove 
excess CV and left to dry overnight. 125 μl of 33% acetic acid was added to each well to 
solubilize the CV. The plate was then read in a microtiter plate reader at O.D. 620nm. This 
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experiment was performed in triplicate. 
Alginate Assay 
 Pseudomonas cultures were grown on PIA plates at 37  C for 48 hours. Plates were scraped 
with a sterile stick and contents added to 0.85% NaCl. Cells were centrifuged to separate alginate 
from the cell. Supernatant was removed and stored in a separate tube. Three milliliters of 
Sulfuric Acid/borate solution (Appendix) was transferred to glass tubes on ice and 350 μl of the 
supernatant was layered on top. A standard curve was made from alginic acid in amounts of: 5, 
50, 100, 200, 300, 600, and 1000 μg/ml. Tubes were vortexed for 1 second and put back on ice. 
One hundred microliters of 0.1% Carbazole in Et H was added and vortexed. Tubes were then 
placed in a 55  C water bath for 30 minutes (20). Tubes were removed and allowed to set at RT 
for 5 minutes. Absorbency was measured at O.D. 530nm. This experiment was performed in 
triplicate. 
Reverse Transcriptase PCR(RTPCR) 
 The GoScriptTM Reverse Transcription System by Promega was used to produce cDNA. 
Both random primer (data not shown) and specific primer were used to generate cDNA. Isolated 
RNA from PA 1 was quantified and 5μg was used. The RNA, 1 pmol of primer, nuclease free 
water to a volume of 5 μl were added to a PCR tube. This tube was incubated at 70°C for 5 
minutes and then placed on ice. The tube was incubated at RT for 5 minutes with the addition of 
4 μl of GoScriptTM 5  Reaction Buffer, 2 μl of MgCl2, 1 μl of PCR Nucleotide Mix, 20 units of 
Recombinant RNasin® Ribonuclease Inhibitor, 1 μl of GoScriptTM Reverse Transcriptase, and 
1.5 μl Nuclease-Free water. The extension step was incubated at 42°C for 1 hour. The Reverse 
Transcriptase was incubated at 70°C for 15 minutes to inactivate the enzyme. cDNA samples 
were incubated at -20°C until time for PCR. A negative control was also performed without 
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Reverse Transcriptase. The PCR that followed had a shorter series of cycle repeats, 26, versus 
the PCR used to generate the genomic DNA control with 30 cycle repeats. Results were run on a 
1% agarose gel and performed in triplicate with 2 different RNA preps. 
Statistical Analyses 
 Where applicable, experiments performed in triplicate were subject to mean, standard 
deviation, and standard error analysis. Graphs show means and standard error via error bars. 
Student’s t test was also performed to confirm significance within each experiment. Stars show 
statistical significance with 1 star having a p<0.05 and 2 stars having a p<0.01. 
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CHAPTER 3 
RESULTS 
Transposon Mutant Screen 
 By using the rsmA-lacZ transcriptional fusion designed from the primer extension data 
(Figure 2), we looked at rsmA expression in the mucoid strain, mucA22, versus the wildtype 
strain PAO1(Figure 4). After seeing a significant increase in rsmA expression, we set out to 
identify possible regulators of rsmA causing this significant increase in expression.  To identify 
regulators of rsmA, 
 
 
Figure 4. rsmA expression is increased in a mucA22. PAO1 and the isogenic strain mucA22 were 
both analyzed via β-galactosidase assay with the transcriptional fusion rsmA-lacZ. 
 
we created a transposon mutant library with the parent strain mucA22 rsmA-lacZ and the 
transposon vector pBT20 (Figure 5). 
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Figure 5. A representation shows conjugation between transposon vector with Gm
R 
gene and 
mucA22 rsmA-lacZ to visualize the creation of transposon mutants. 
 
Patch Plating 
 Transposon mutants were picked from PIA gentamicin plates with a sterile toothpick. Only 
colonies that were isolated as a single colony were chosen to avoid contamination. Growing 
colonies on PIA gentamicin plates ensured that there would be no E. coli due to irgasan and no 
parent mucA22 rsmA-lacZ without the transposon and Gm
R 
genes. X-gal was added to visualize 
differences in rsmA expression levels. Because it can take up to 48 hours for alginate to 
accumulate from the patched colony, plates were observed over the course of 2 days to look for a 
mucoidy appearance. In terms of β-galactosidase activity on the plates, after incubating 
overnight, the plates were left at room temperature for an hour to let blue color develop further 
(Figure 6). The patched mutants were compared to a patched colony of mucA22 rsmA-lacZ. 
Those colonies that were drastically darker or lighter than the parent strain with the 
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transcriptional fusion were then streaked for isolation on PIA gentamicin plates. The plates were 
incubated overnight. Freezer stocks were made for storage of the transposon mutants of interest 
and those mutants were also subject to β-galactosidase assay. 
 
 igure 6. Patched transposon mutants on a PIA 80 μg/ml  -gal 150 μg/ml gentamicin plate. The 
blue pigment is a result of rsmA expression from the rsmA-lacZ transcriptional fustion. 
 
β-Galactosidase Assay 
 Over 50 transposon mutants have been screened via the β-galactosidase assay since the 
start of our project looking for regulators of rsmA. The assay was performed with 16-hour 
cultures. The mutants that we analyzed were performed in triplicate to assure that the assay was 
consistent. We also compared results of broth versus cultures grown on a plate to look for 
variances in rsmA expression between the 2 environments. Student’s t test was performed on the 
values of the individual transposon mutants and mucA22 rsmA-lacZ to look for significant 
differences between the 2 (Figure 7). If the p value was less than 0.05, we considered it a 
significant difference to further study the transposon mutant by identifying the interrupted gene. 
We have identified 50 signficiant mutants by this method, 20 of which have exhibited very 
significant differences. The most drastic difference we have seen is a fourfold decrease in rsmA 
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expression. Some mutants were identified by arbitrary PCR for their interesting appearance or 
odd growth patterns on plate medium. 
 
Figure 7. β-Galactosidase Assay results with t test analysis. This experiment was performed in 
triplicate to ensure the least amount of error. mucA22 rsmA-lacZ was our standard we compared 
the transposon mutants to in this experiment. One star signifies p<0.05 and 2 stars signify 
p<0.01. 
 
Arbitrary PCR 
 The original arbitrary PCR protocol called for adding all 3 primers to amplify the 
transposon interrupted region (30). However, we found that we had more success using the 
arbitrary primers individually instead of used together as the protocol suggests. We also 
discovered that Arb1 and Arb2 primers were more successful at amplifying segments to be 
sequenced than Arb3. Samples were sent to the ETSU Molecular Biology Core to be sequenced. 
We used the program Chrome to analyze the results and then BLAST the sequence on 
http://www.pseudomonas.com to identify which gene was interrupted (41). Based on our β-
galactosidase assay, Table 7 lists 9 genes that have been identified to regulate rsmA expression in 
P. aeruginosa, one previously identified in another study. pilW was the first to be identified in 
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this experiment. An individual project revolving around the minor pilin gene was begun at that 
time, but we continued to identify genes. Another important gene identified by arbitrary PCR 
was retS. RetS is a negative regulator of the GacA/S 2 component system, which in turn favors 
production of RsmA (27). 
 
 PA1626 is another gene of interest from this study, which we named mtpX. Our β- 
galactosidase assay showed a 4-fold decrease when compared to mucA22 rsmA-lacZ. Other 
mutants ranged from a two-thirds increase (dsbA) to almost fivefold decrease (PA1192) in terms 
of Miller units measuring rsmA expression. The mucoid strain became nonmucoid as well as had 
very decreased levels of rsmA expression via the lacZ reporter. After identifying this gene via 
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sequencing, we set out to make a knockout of mtpX in order to confirm our results from the 
transposon insertion. Like pilW, mtpX was in an operon, but it is located next to a transcriptional 
regulator. This transposon insertion could have complicated our results by interrupting the 
message of both genes. We then began to make a knockout mutant of mtpX. 
Mutant Construct 
 Two genes, pilW and mtpX, were selected for making mutants to compare results with the 
transposon mutants. Primers were designed to amplify segments surrounding the gene of interest 
(Figure 8). These segments were then spliced together to create the deletion construct. 
 
Figure 8A. Diagram showing Construction of mutant strains 
 
 The individual 5’ and 3’ fragments were successfully amplified as a single amplicon of 
approximately 1000bp and were gel purified without UV exposure as well as ethidium bromide 
that might have damaged DNA. The 5’ and 3’ pieces were successfully used as templates in a 
second PCR using primers, F1 and R1 (Figure 8B). 
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 igure 8B. 1% agarose gel used to show amplified 5’ and 3’ segments along with S E amplified 
segment. MW is molecular weight marker used to measure amplified segments of DNA. 
 
 This mutation construct was digested along with both a cloning vector and suicide vector. 
We used a cloning vector as a precaution in case more knockout constructs were required. The 
mutant construct was then ligated into the suicide vector and then transformed in E. coli. The 
mutant construct was conjugated into various P. aeruginosa strains. After making merodiploids, 
which are cells with both mutant and wildtype genes, we left them to perform homologous 
recombination in LB broth overnight. This broth was serially diluted on 10% sucrose LB plates. 
The second crossover was successful as determined by detection of the mutant allele on sucrose-
resistant colonies after PCR analys using primers (Appendix). After completing the mutant 
screening successfully and confirming the mutation with internal detection primers, freezer 
stocks were made of the mutants. We made mutants in both mucoid and nonmucoid 
backgrounds. 
Growth Curves of ΔmtpX Mutants 
 One possible explanation for the differential rsmA expression in the transposon mutants is 
that these mutants have a growth defect due to the transposon insertion. To address this 
possibility, we performed growth curve analysis of the constructed mtants compared to the wild 
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type strains. As the mtpX mutant may have a arole in supplying nutrients to the cell, we analyzed 
the growth kinetics of this strain in several media, both complex and minimal media. 
In LB Media 
 In LB broth, there was no difference between the mutants and the parent strains. PAO1 had 
a spike in the O.D. reading at 12 hours, but overall there was no difference. This growth curve 
analysis was performed in triplicate to ensure that there was no difference between growth of the 
mutants and PAO1 or mucA22. These results can be seen in Figure 9. In addition our results 
demonstrate that in complex media there is both the nonmucoid PAO1 and the mucoid strain, 
mucA22, have similar growth kinetics. 
 
 
Figure 9. Growth Curve analysis of mtpX mutants versus PAO1 and mucA22 show no variation 
in growth. PA 1(blue diamond), PA 1∆mtpX(red square), mucA22(green triangle), and 
mucA22∆mtpX(purple X) were grown in LB broth over 24 hours. Standard error bars are shown 
at each time point. 
 
In Minimal Media 
 Because MtpX may play a role in the metabolism of P. aeruginosa, we compare the 
growth of the mtpX mutant to the parent strain in minimal media using different carbon sources. 
M9 salts minimal media and an added carbon source; either glucose or succinate was used. 
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 1% Glucose.  P. aeruginosa does not readily metabolize sugars like glucose, sucrose, and 
lactose (9). However, it can still grow using glucose as the sole carbon source. There again was 
no difference in growth between the mutants and parent strains (Figure 10). However, there was 
a visual difference in growth. Around the 12 hour time point, PA 1, PA 1∆mtpX, and 
mucA22∆mtpX, all changed color of their media to a red pigment, which we predict is secreted 
pyorubin, while mucA22 remained yellow in color. It is interesting to note the difference in the 
mucA22∆mtpX. This mutant was able to secrete pyorubin with the inner membrane protein MtpX 
removed from the cell in the mucoid background. 
 
Figure 10. Growth Curve Analysis in 1% Glucose minimal media shows no variations between 
mutants and parent strains. PA 1(blue diamond), PA 1∆mtpX(red square), mucA22(green 
triangle), and mucA22∆mtpX(purple X) were grown in minimal media broth over 24 hours. 
Measurements were recorded at O.D. 600nm. 
 
 1% Succinate.  Succinate is readily metabolized by P. aeruginosa. This carbon source also 
increased pyoverdine secretion. There was no difference in growth analysis (Figure 11). The 
strains also exhibited pigment change at the same time. 
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Figure 11. Growth Curve Analysis in 1% Succinate minimal media shows no variations between 
mutants and parent strains. PA 1(blue diamond), PA 1∆mtpX(red square), mucA22(green 
triangle), and mucA22∆mtpX(purple X) were grown in minimal media broth over 24 hours. 
Measurements were recorded at O.D. 600nm. 
 
β-Galactosidase Assay of ΔmtpX Mutants with rsmA-lacZ Fusion 
 In order to confirm our transposon mutant results from the β-galactosidase assay, we 
inserted the rsmA-lacZ fusion into the knockout mutant’s chromosome of both backgrounds. 
These were performed from broth cultures and done in triplicate (Figure 12) with t tests to show 
significance. We not only repeated our transposon mutant results in this knockout mutant but 
also showed a significant decrease in the nonmucoid background strain PAO1. This confirms the 
transposon screen results and suggests that MtpX affects rsmA expression by some undefined 
mechanism. 
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 igure 12. Β-galactosidase assay shows significant decreases in ΔmtpX mutants’ rsmA 
expression. Miller units were calculated from recording O.D. 600nm, 420nm, and 550nm during 
the course of the assay using Miller’s equation.  ne star represents a p<0.05 and two stars, a 
p<0.01. 
 
RNase Protection Assay of ΔmtpX Mutants with rsmA Probe 
 As transcriptional fusion analysis is one way to analyze gene expression, it uses a reporter 
gene controlled by the promoter of the gene of interest. This provides an indirect measurement of 
gene expression. In order to directly measure the amount of rsmA message, we performed an 
RNase protection assay. A probe consisting of biotinylated rsmA antisense message was 
produced by invitro transcription, gel purified, and used in a hybridization experiment using total 
RNA isolated from various strains. The RNA probe was combined with RNA isolated from each 
of the 4 strains (Figure 13). RNA was isolated at 6 to 8 hours from broth cultures, so there is 
potential for change in results when compared to rsmA expression using a transcriptional fusion 
measured at 16 hours. However, when comparing PAO1 and mucA22 we see darker bands in the 
mucoid background versus the nonmucoid. The protein simple Fluoro Chem M imager was used 
to confirm analysis of the intensity of the bands present (data not shown). 
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Figure 13. RNase Protection Assay with ΔmtpX mutants. These results show that the nonmucoid 
mutant is actually increasing rsmA expression via the AlgU promoter while the mucoid 
background mutant has less expression than that of mucA22. A negative control was used with 
yeast RNA and the rsmA probe. The top arrow marks the band transcribed from the AlgU 
promoter while the lower arrow shows the unknown promoter. 
 
 We see 2 bands as well, which indicates that there are 2 rsmA messages. This result is 
supported by the primer extension results demonstrating that there are 2 transcriptional start sites 
(Figure 3). The longer message is from the AlgU-dependent promoter while the lower band is 
controlled by an unknown sigma factor. 
 These results vary from the β-galactosidase assay, which showed decrease in rsmA 
expression in the nonmucoid mutant. The only variable here is time of experiment. We showed 
(Figure 2) that RsmA is diminished greatly between 6 hours and 12 hours in PAO1 and this may 
explain our RNase protection assay results. Two bands can be seen in the 2 parent backgrounds, 
PAO1, and mucA22. The messages appear more intense in the mucoid background supporting 
our β-galactosidase assays. However, the mtpX mutant has a great deal more message from the 
AlgU-dependent promoter and a very faint band representing the second message. This result 
suggests that there is more rsmA message from the AlgU promoter and this may be due to 
different RNA concentrations or different levels of RNA degradation. 
 In the mucoid background, we confirm our β-galactosidase results. The top band in the lane 
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with the mucA22ΔmtpX is slightly lighter in appearance when compared to mucA22. The second 
band, however, is significantly lighter than that of mucA22. The correlation between both these 
messages has not been elucidated and how much they effect the β-galactosidase results is 
unclear. Another time course experiment using the RNAse protection assay may be useful in 
seeing the expression of the various messages in both mucoid and nonmucoid background. We 
also have a construct consisting of a site-directed mutation of the AlgU promoter of rsmA and 
would like to repeat this experiment to confirm that these results are consistent with our primer 
extension data showing the presence of 2 messages as well to prove the results of the PAO1 
mtpX mutant. 
Western Blot Analysis of ΔmtpX Mutants with HA Tagged RsmA 
 An alternative way to look at rsmA expression is to determine the levels of RsmA in the 
cells. We confirmed the presence of the HA tag via PCR and running the amplified products on a 
1% agarose gel. The mtpX mutants were made by conjugating the ΔmtpX construct with PAO1 
and mucA22 strains with the HA-tagged RsmA already inserted on the chromosome. Using an 
HA- tagged RsmA, we were able to analyze the abundance of RsmA in the various strains. These 
cultures were taken from LB plates to reduce the amount of alginate produced by mucA22. The 
strains were grown for 12 hours, lysed, and 12 μg of protein was loaded into each well. We saw a 
very different result in our Western Blot (Figure 14). PAO1 showed more RsmA present than 
that of mucA22. This is  
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 igure 14. Western Blot of ΔmtpX mutants with HA-tagged RsmA. 20μg of protein was used. 
PAO1 without HA-tagged RsmA was used as a negative control. The arrow marks the HA- 
tagged RsmA and its size of approximately 7 kDa. When 20 μg of protein is loaded, 
PA 1∆mtpX appears to have more HA-tagged RsmA(data not shown). 
 
contrary to our β-galactosidase and RNAse protection assays. The nonmucoid background does 
not seem to be affected by the removal of mtpX; however this may be because 20 μg were loaded 
on the SDS-PAGE. For the mucoid background, we see the same decrease in the mtpX mutant as 
reported before in other assays. This experiment was repeated twice to confirm the results 
because there was no presence of RsmA detected in the mucA22ΔmtpX strain. 
Motility Assays 
 Having patched the mtpX mutants multiple times on various plates, we noticed that there 
were distinct hazes around the regions of growth that looked similar to twitching zones. P. 
aeruginosa is equipped with the ability to swim via flagella and twitching via type IV pili. 
Because mucoid strains aren’t supposed to be as motile as nonmucoid strains, we decided to 
screen the mtpX mutants in various motility assays. 
Swimming Assay Shows Increase in Mucoid Background ∆mtpX 
 The swimming assay was performed on LB plates with 0.3% agar. After incubating for 48 
hours at 30°C, the zones of swimming were measured. Because the medium is not as thick, 
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bacteria use their flagella to “swim” through the medium. P. aeruginosa’s ability to swim varies 
upon the strain. Here we looked at the mutants in both backgrounds (Figure 15). PAO1 and its 
mtpX mutant showed no real difference in swimming. The mucA22 strain is not supposed to 
express flagella; instead it is supposed to be more stationary. However, the mucA22ΔmtpX 
mutant swam more than mucA22 and PAO1. At the time we did not know why this occurred or 
how it may relate to RsmA levels in the cell. We decided to look at twitching in these mutants as 
well. 
 
 
 
 
Figure 15. Swimming Assay of mtpX mutants and parent strains. mucA22∆mtpX was the only 
significant result in the swimming assay. Zones of growth were measured in centimeters. Two 
stars represent a p<0.01. 
 
Twitching Assay Shows Increase in Mucoid Background While Decreased in Nonmucoid 
Background 
 The twitching assay looks at the ability of bacteria to propel themselves through a thicker 
media, 1.5% agar media. We showed that the inner membrane protein MtpX has some effect on 
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twitching in both backgrounds (Figure 16A). Zones are measured after the agar is removed and 
have been stained with crystal violet ( igure 16B). PA 1ΔmtpX showed a decrease in twitching 
ability, almost to the level of mucA22, which is not able to twitch. However, similarly to the 
swimming assay the mucA22ΔmtpX strain was able to outperform PAO1 in twitching zones and 
was drastically different from mucA22. 
 
 igure 16. Twitching Assay showing the effects of ΔmtpX on type IV pili in both mucoid and 
nonmucoid backgrounds. A. Measurements in millimeters of twitching zones. B. Images of 
crystal violet stained twitching zones under their respective strain. 
 
Transmission Electron Microscopy (TEM) of ΔmtpX Mutants 
 Because the motility assays were presenting such interesting results, we set out to visualize 
the cell surface via TEM. We found that 2% UA provided the best results in visualizing the cells 
with the TEM when compared to 2% phosphotungstic acid (PTA). The most alluring data, the 
mtpX mutants, show the presence of flagella on their cells. PAO1 (Figure 17A) is our wildtype 
strain that can express either flagellum or type IV pili. We have shown through the motility assay 
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that both conditions are possible depending on the type of media used.  n the PA 1ΔmtpX cell 
(Figure 17C), we see a single polar flagellum. This image explains the mutant strains ability to 
swim but not twitch. In the mucoid background, we see mucA22 (Figure 17B) secreting 
exopolysaccharide and the cell also has cellular appendages. However, the 
 
Figure 17. Transmission Electron Microscopy of PAO1(A), mucA22(B), PA 1ΔmtpX(C), and 
mucA22ΔmtpX(D). Black arrows designate single polar flagellum. 
 
mucA22ΔmtpX cell (Figure 17D) shows small amounts of exopolysaccharide and, like the 
PA 1ΔmtpX cell, a single flagellum. This explains our swimming results. 
 
Siderophore Production Increases in Mucoid Background ∆mtpX 
 Mutant strains growing on both LB and PIA plates were producing an unusual amount of 
yellow-green pigment extending from areas of growth. Under the presence of ultraviolet(UV) 
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light, the green pigment fluoresced, which is a trademark of pyoverdine, an iron-binding 
compound produced by P. aeruginosa. We made CAS plates in order observe the production of 
pyoverdine. When iron is sequestered by siderophores, the iron-dye complex of the plate turns 
from blue to orange when pyoverdine is produced (21). Here we measured the orange zones to 
see if the mtpX mutants were producing more pyoverdine than PAO1 and mucA22 (Figure 18A). 
We also exposed the patched strain to UV light to confirm we were actually seeing pyoverdine 
(Figure 18B). mucA22ΔmtpX showed a significant increase in siderophore production when 
compared to mucA22 and was statistically significant in this experiment. 
 
Figure 18. Measured zones of pyoverdine in millimeters (A). Plates exposed to UV light (B) 
under their respective strain. 
 
Biofilm Assay Shows Decrease in Nonmucoid Background ΔmtpX Mutant 
 P. aeruginosa is well known for its production of biofilm by secreting exopolysaccharide 
on both biotic and abiotic surfaces. Our mucoid strain mucA22 produces a very thick biofilm of 
alginate. We set out to see if our mtpX mutants have decreased production of biofilm. When P. 
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aeruginosa is expressing flagella, it is not as likely to be producing biofilm. We also saw a 
drastic phenotypic change in the mucA22∆mtpX strain, which we assumed affected biofilm. We 
performed a microtiter biofilm assay (31) and determined the amount of biofilm that adheres to 
the polystyrene sides using crystal violet and spectrophotometry (Figure 19A). We also looked at 
patch plating the strains on to Congo Red media (Appendix) (Figure 19B) for any difference in 
appearance on this media. The Congo Red dye will bind exopolysaccharide secreted by cells, 
with red or purple strains expressing more biofilm (22). 
 
Figure 19. Microtiter Biofilm Assay of ∆mtpX mutants, measured at O.D. 620nm(A). 
PA 1∆mtpX was the only strain to show any difference in biofilm production. One star 
represents a p<0.05. Strains patch plated on Congo Red media (B) show no drastic color 
appearance. 
 
The PA 1∆mtpX strain exhibited a decrease in biofilm production, while the mucA∆mtpX 
showed no difference in biofilm production. 
Alginate Assay Shows Decrease in Mucoid Background ΔmtpX 
 The biofilm assay did not give us the results we expected, so we decided to perform an 
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alginate assay because of the visual appearance of the mucA∆mtpX. The mucA∆mtpX showed a 
significant decrease in alginate production (Figure 20). These results confirmed that MtpX is 
required for alginate production. The amount of alginate was quantified via a standard curve. 
This experiment was performed in triplicate. As indicated in Figure 20, the mucA22ΔmtpX 
mutant had an almost 2000-fold reduction in alginate. This is the first description of this 
transporter playing a role in alginate production. 
 
 igure 20. Quantification of alginate produced by ∆mtpX mutants (A) and images of strains on 
PIA plates (B). mucA22∆mtpX showed a significant decrease in alginate production. Two stars 
represent a p<0.01. 
 
Reverse Transcriptase PCR on mtpX/PA1627 Operon 
 Besides phenotypically analyzing the ∆mtpX mutants, we wanted to characterize the mtpX 
messenger RNA. Bioinformatic data suggest that mtpX is in an operon with the upstream gene, 
PA1627, a probable transcriptional regulator. Using gene sequence from pseudomonas.com, we 
designed primers to produce cDNA for the mRNA containing both mtpX and PA1627 (41). 
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Forward primers were located at the start of the intergenic space between PA1628 and PA1627, 
the start of PA1627, and the middle of PA1627. Our results (Figure 21) showed that PA1627 and 
mtpX were indeed transcribed in the same message. However, the significance of these results 
has not been elucidated. 
 
Figure 21. RT-PCR of PA1627/mtpX operon to confirm these 2 genes were in an operon. 
Genomic DNA was used as a positive control. RNA without reverse transcriptase was used as a 
negative control to ensure there was no genomic DNA contamination. Amplified products were 
run on a 1% agarose gel. Location of primers on a genomic model is shown below the gel. 
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CHAPTER 4 
DISCUSSION 
 P. aeruginosa is a virulent opportunistic pathogen notorious for causing complications in 
immunocompromised individuals and nosocomial infections. An understanding of how P. 
aeruginosa uses its virulence factors to cause infections could lead to better chemotherapeutic 
treatment of this pathogen. By studying the global regulator RsmA, we have not only learned 
more about the network of virulence factors it controls but also the regulators of rsmA’s 
expression. 
rsmA Regulators 
 The screen to identify rsmA regulators has increased our knowledge of how this important 
posttranscriptional regulatory system is controlled. pilW was interrupted in the mucoid strain 
mucA22, which is thought to not express type IV pili(4). However, when the transposon 
interrupted the minor pilin gene, we saw a significant decrease in rsmA expression. Because pilW 
is in an operon with 6 other pilin genes, we made a knockout mutant of pilW to confirm our 
transposon results. We found PilW does affect rsmA expression in this background (data not 
shown) and have set out further to study the effects it has on RsmA. Another interesting gene to 
study will be the probable transcriptional regulator PA2028. We still have to knockout this gene 
and to determine its effects on RsmA’s antagonists, RsmY and RsmZ. Lastly, there is mtpX the 
probable major facilitator superfamily transporter. MtpX shows weak homology to CynX, a 
cyanate permease in E. coli with 33% identical residues and 54% similar residues (15,16,32). In 
P. aeruginosa there are 2 other genes that are more homologous to CynX. Since only a few parts 
of Mtp ’s cellular function have been elucidated ( igure 22) in both mucoid and nonmucoid 
backgrounds of P. aeruginosa, we are looking to further study this inner membrane transporter. 
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 We have shown that there is a definitive relationship between the expression of rsmA and 
Mtp . After confirming the transposon mutant with β-galactosidase assays of a ΔmtpX mutant, 
we discovered divergent results in our 2 backgrounds (Figure 20). In the mucoid background, we 
saw a slight decrease in the 2 mRNAs of rsmA via RNase Protection Assay. 
 
Figure 22. Mechanism proposal of MtpX representing the mucoid strains (A) and nonmucoid 
strains (B). Arrows denote an up-regulation while squares represent down-regulation of genes. 
 
  ur Western Blot analysis also confirmed the loss of RsmA in the ΔmtpX mutant. We have 
seen through β-galactosidase assays that RsmY and RsmZ greatly increase in the mucoid 
background. This may explain the loss of RsmA from the Western Blot in the mucA22 ΔmtpX 
strain as the decreased levels are bound by RsmA’s antagonists. We can pursue this answer by 
using a rsmY- lacZ and rsmZ-lacZ fusion and confirming the results with RNAse Protection 
Assays. We can also look at RsmA with a Western Blot in mucA22ΔrsmYΔrsmZ and 
mucA22ΔrsmYΔrsmZΔmtpX mutants with HA-tagged RsmA. If RsmY and RsmZ are factoring 
into the levels of RsmA in the ΔmtpX mutant, either of these experiments would explain the 
results. Contrarily, MtpX may regulate RsmY and RsmZ. Because we saw a disappearance of 
RsmA levels via the Western blot analysis in the mucoid background, MtpX could down regulate 
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the expression of rsmY or rsmZ. By looking into rsmY and rsmZ expression in the mucoid 
background, increases in expression of these 2 small RNA may explain our rsmA results. We can 
also overexpress rsmY and rsmZ in the nonmucoid background, to see if the results are opposite 
and RsmA levels decrease (35). In the RNase Protection Assay and Western blot analysis, we 
saw contrasting results between nonmucoid and mucoid backgrounds. 
 For the case of the nonmucoid background, we saw a marked increase in the rsmA mRNA 
with AlgU promoter. We can confirm that MtpX affects AlgU by knocking out AlgU and 
performing another RNase protection assay in this double mutant with the rsmA probe, as well as 
looking examining RsmA levels in an algU mutant strain. After completing this series of 
experiment, we may be able to better understand the role MtpX shares with rsmA expression. 
Characterizing MtpX 
 Seeing the transposon mutant revert from the mucoid mucA22 rsmA-lacZ strain to a 
nonmucoid variant was concerning at first. After repeatedly making the knockout mutant in 
mucA22 and also our 2 mucoid CF clinical isolates, FRD1 and 2192, it was clear that the MtpX 
transporter plays an important role in alginate production. This may provide a new 
chemotherapeutic target that may help eradicate P. aeruginosa infections in cystic fibrosis 
patients (7). The most interesting effect of knocking out the mtpX gene, besides loss of alginate 
production, is the appearance of flagella on the P. aeruginosa cells. Dispersion mechanisms are 
en vogue currently in Pseudomonas pathogenesis research and MtpX may play a role in biofilm 
dispersion given that the mucA22ΔmtpX demonstrated increased swimming compared to the 
mucA22 parent. Even though our biofilm assays did not detect a difference in biofilm formation 
using the microtiter plate assay, we did not specifically examine biofilm dispersal. This will be 
the subject of further investigation. Additionally, the overespression of pyoverdine suggests that 
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the mucA22ΔmtpX mutant may have a problem acquiring iron or in overproducing exzymes 
requiring iron. Further investigation of this mutant will provide important insights into the 
pathogenic mechanisms used by P. aeruginosa. 
 Further investigations analyzing the transcriptional regulation of the mtpX genomic region 
are underway. This will include mapping the transcriptional start site of PA1627 by primer 
extension. In doing so, we will be able to possibly identify the promoter of this operon.  It is also 
in our interest to make a knockout mutant of PA1627 in both mucoid and nonmucoid 
backgrounds and look at the effects on rsmA expression. Because PA1627 is a transcriptional 
regulator, it could possibly auto regulate the mtpX-PA1627 operon. Additional studies into the 
regulation of this system are needed to identify new possible drug targets. Isolating the MtpX 
protein and clarifying the substance it transports will also be crucial to closing the chapter on this 
regulator of rsmA expression. Although there are still more questions to answer, we feel that 
Mtp  may prove to be an important resource not only in RsmA’s cellular role but also the 
pathogenicity of Pseudomonas aeruginosa. 
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APPENDICES 
Appendix A: Media 
 
PIA (1 Liter) 
 
935 ml ddH2O  
20 ml Glycerol 
bring to boil 
 
Add: 
20g Peptone 
10g Potassium Sulfate  
13.6g Agar 
1.4g Magnesium Chloride  
25mg Irgasan(irg) 
 
Autoclave 
Antibiotic concentrations:  
150 μg/ml gentamicin 
80 μg/ml  -gal 
 
LB (1 Liter) 
 
940 ml ddH2O  
15g Agar 
10g NaCl 
5g Yeast Extract  
10g Tryptone 
 
Autoclave 
 
Antibiotic concentrations:  
15 μg/ml gentamicin 
10 μg/ml tetracycline 
100 μg/ml ampicillin 
50 μg/ml kanamycin 
 
LB no NaCL tet
50 
irg
25 
(1 Liter)  
same as LB, just no salt added  
25 mg Irgasan 
 
Autoclave 
 
50 μg/ml tetracycline 
 
1% agarose gel (for 2 gels) 
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0.5 g Agarose  
5 ml 10X TBE  
45 ml ddH2O 
 
Microwave for 1 minute 
 
Add 2.7 μl Ethidium Bromide when container is warm to touch 
 
M9 salts 
10X M9 salts (500 ml)  
30g Na2HPO4 
15g KH2PO4 
2.5g NaCl 
5g NH4Cl 
pH to 7.4 
 
For 100ml of broth:  
10ml 10X M9 salts 
0.2 ml 1M MgSO4 
0.1 ml 0.1M CaCl2 
0.1 ml 1M thiamine HCl 
 
Add 1% carbon source of interest. 
 
VBMM 
500 ml 10X VBMM stock 
 
400 ml ddH2O 
15g Trisodium Citrate  
10g Citric Acid 
50g K2HPO4 
17.5g NaNH4PO4 · 4H2O  
pH to 7 and autoclave 
 
plates (500ml): 
 
400 ml ddH2O 
7.5g Agar 
autoclave and allow to cool to 50°C  
50 ml 10X VBMM 
500 μl 1M Magnesium Sulfate 
50 μl 1M Calcium Chloride 
 
Antibiotics: 
300 μg/ml Carbenicillin 
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M63 minimal media broth(31)  
5X M63 stock: (1 Liter)  
15g KH2PO4 
35g K2HPO4 
10g (NH4)2SO4 ddH2O to 1L 
 
Broth final concentrations:  
1X M63 
1% Glucose 
1mM MgSO4 
1% Glycerol 
0.5% Casamino acids 
0.4% Arginine 
sterile ddH2O to final volume desired 
 
Congo Red(22) 
5g Tryptic Soy Broth  
6.7g Agar 
460 ml ddH2O 
 
Autoclave and cool to 50ºC 
 
Congo Red 40μg/ml Coomassie Brilliant Blue 20μg/ml 
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Appendix B: Buffers 
 
10X TNE 
830 ml ddH2O  
12.1g Tris Base  
3.7g EDTA  
116.8g NaCl 
 
1X TBS-T 
10X TBS: 
12.1g Tris base  
43.8g NaCl  
ddH2O to 500 ml 
 
1X TBST: 
100 ml 10X TBS  
500 μl of Tween 20  
ddH2O to 1 L 
 
10X TE 
108g Tris Base  
55g EDTA  
900 mL ddH2O 
 
Z Buffer 
900 ml ddH2O 
16.1g Na2HPO4 · 7H2O  
5.5g NaH2PO4 · H2O  
0.75g KCl 
0.246g MgSO4 · 7H2O 
pH to 7 and autoclave 
 
Add 2.7 μl/ml of β-mercaptoethanol when ready to use 
 
10X TBE 
108g Tris Base  
55g Boric Acid 
40 ml 0.5M EDTA  
900 ml ddH2O 
 
TEST Buffer 
500 μl 1M Tris 
120 μl 0.5M EDTA 
1.5 ml 50% sucrose 
500 μ 10% Triton  -100 
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4x SDS Loading Buffer 
4.4 ml 0.5M Tris HCl pH6.8  
4.4 ml Glycerol 
2.2 ml 20% SDS 
0.5 ml 1% Bromophenol Blue  
0.5 ml β-mercaptoethanol  
Store at -20ºC 
 
10X Glycine Running Buffer  
30.3g Tris Base 
144.1g Glycine 
10g SDS 
ddH2O to 1L 
 
1.5M Tris HCl pH 8.8  
27.23g Tris base 
80ml ddH2O 
adjust pH to 8.8 with 6N HCl 
 
ddH2O to 150 ml 
 
0.5M Tris HCl pH6.8  
6.1g Tris base 
80ml ddH2O 
pH to 6.8 with 6N HCl  
 
ddH2O to 100 ml 
 
Towbin Buffer 
10X Towbin Buffer:  
30.3g Tris base  
144g Glycine  
ddH2O to 1 L 
 
1X Towbin buffer for Electroblotting:  
10 ml 10X Towbin buffer 
20 ml Methanol 
70 ml ddH2O 
 
Blocking Buffer 
2.5g Skim Milk powder  
5 ml TBS-T buffer 
45 ml ddH2O 
 
1° antibody Wash 
2.5g Skim Milk powder 
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5 ml TBS-T buffer 
45 ml ddH2O 
2.5 μl of HA-tag antibody 
 
Washing Buffer 
5 ml TBS-T buffer  
45 ml ddH2O 
 
2° antibody Wash 
2.5g Skim Milk powder 
5 ml TBS-T buffer 
45 ml ddH2O 
2.5 μl of anti-goat/anti-mouse antibody 
 
Sulfuric Acid/Borate Solution  
975 ml Sulfuric Acid 
25 ml Borate Solution 
 
Borate Solution 
10.09g KOH in 45 ml of ddH2O  
24.74g Boric Acid 
ddH2O to 100 ml 
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Appendix C: Primers & Plasmids 
 
   Primers 
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Plasmids  
plasmid   Relevant Characteristics    Source or reference 
pBT20   transposon, Gm
R
    (33) 
pMX19   ∆mtp , AmpR     this study 
pRHA18   rsmA-HA, Gm
R
    this study 
pMX18   ∆mtp , TetR     this study 
mini-CTX-AlacZ  rsmA-lacZ, Tet
R
    this study 
pRK2013   used for triparental mating, Kan
R
   (11) 
pFLP2   used for removing mini-CTX, Amp
R
  (39) 
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